baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CENCORA DL-,01/ US03073E1055 /

03/06/2024 08:16:54	Chg. +5.30	Volume	Bid14:15:04	Ask14:15:04	Market Capitalization	Dividend Y.	P/E Ratio
207.30EUR	+2.62%	0 Turnover: 0.00	207.25Bid Size: 50	210.70Ask Size: 50	41.66 bill.EUR	-	-

GlobeNewswire 29/05 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach

GlobeNewswire 28/05 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...

GlobeNewswire 15/05 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...

GlobeNewswire 13/05 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...

GlobeNewswire 09/05 Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...

GlobeNewswire 02/05 Outlook Therapeutics® to Present at the Retina World Congress 2024

GlobeNewswire 29/04 Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...

GlobeNewswire 17/04 2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners

GlobeNewswire 15/04 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

GlobeNewswire 22/03 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...

GlobeNewswire 18/03 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million

GlobeNewswire 18/03 Parexel Announces CEO Succession Plan

GlobeNewswire 12/03 Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split

GlobeNewswire 14/02 Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...

GlobeNewswire 23/01 Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...

GlobeNewswire 02/01 Coherus Announces U.S. Launch of LOQTORZI™

GlobeNewswire 22/12/2023 Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...

GlobeNewswire 19/12/2023 Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...

GlobeNewswire 06/12/2023 Outlook Therapeutics® Announces Strategic Organizational Realignment

GlobeNewswire 27/11/2023 Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path For...

GlobeNewswire 14/11/2023 Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior V...

GlobeNewswire 02/11/2023 Outlook Therapeutics® Provides Update on Type A Meetings with FDA

GlobeNewswire 01/11/2023 Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (IN...

Newsfile Corp 26/10/2023 Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694

GlobeNewswire 29/09/2023 Outlook Therapeutics® Requests Type A Meeting With FDA

CENCORA DL-,01/ US03073E1055 /

If you wish to receive reply to your feedback, please provide your email address.